Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology
Company in Active Discussions with Several Large Pharmaceutical Companies for Potential Joint Venture/Licensing Partnerships for Its Cancer Vaccine Technology Platform
The Company recently reported interim results from a Phase II trial of an Ii-Key modified peptide vaccine for patients treated for breast cancer who are at high risk of relapse. While there was a 7% relapse rate in the control arm there were no relapses in the Ii-Key peptide arm (AE37) when analyzed at the 13-month time point. A review article co-authored by Eric von Hofe, Ph.D., President of Antigen Express entitled ‘A New Era in Anticancer Peptide Vaccines’, appeared in the journal Cancer, published by the American Cancer Society.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.